Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Prescient Therapeutics Ltd (PTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.059 -0.003    -4.84%
16:04:59 - Closed. Currency in AUD ( Disclaimer )
  • Volume: 531,177
  • Bid/Ask: 0.058 / 0.059
  • Day's Range: 0.058 - 0.062
Type:  Equity
Market:  Australia
ISIN:  AU000000PTX3 
Prescient Therapeutics Ltd 0.059 -0.003 -4.84%

Prescient Therapeutics Ltd Company Profile

 
Get an in-depth profile of Prescient Therapeutics Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

3

Equity Type

ORD

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.

Contact Information

Address 100 Albert Road Level 4
Melbourne, 3205
Australia
Phone 61 3 9692 7222
Fax 61 3 9077 9233

Top Executives

Name Age Since Title
Steven B. Engle 66 2014 Independent Non-Executive Chairman
Yatomi-Clarke Steven Lee - 2014 MD, CEO & Director
Rodney Daniel Sinclair - 2011 Chairman of Clinical Advisory Board
Allen Ebens - 2020 Non-Executive Director
Phillip Darcy - 2020 Member of Scientific Advisory Board
James A. Campbell - 2014 Independent Non-Executive Director
Andrew Tsourkas - 2021 Member of Scientific Advisory Board
Marco L. Davila - 2021 Member of Scientific Advisory Board
Ellen Gwen Feigal 69 2023 Independent & Non- Executive Director
Joshua Douglas - 2014 Member of Scientific Advisory Board
Thomas Prebet - 2016 Member of Scientific Advisory Board
Reinhard Dummer - 2011 Member of Clinical Advisory Board
Jeffrey Lancet - 2015 Member of Scientific Advisory Board
Donald M. O’Rourke - 2021 Member of Scientific Advisory Board
Farhad Ravandi - 2015 Member of Scientific Advisory Board
H. Miles Prince - 2020 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PTX Comments

Write your thoughts about Prescient Therapeutics Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Abu zade
Abu zade Sep 27, 2019 20:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
out for now
Abu zade
Abu zade Sep 24, 2019 12:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looking good
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email